STEP 5 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Yuki Morishita
Page 6 of 8 of this archive, newest first.
Archive — page 6
142 piecesWhat actually helps, ranked by evidence
The intervention with the clearest evidence is the one nobody frames as an intervention: adjusting the dose.
What STEP 4 tells us about maintenance, and what it does not
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
Holding a dose is a decision, not a failure
Reducing a dose is not going backwards. In a tolerability-limited class it is the mechanism by which the ceiling is found.
SURPASS-2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
STEP 4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Monitoring intervals, and the case against measuring too often
A panel that will not change a decision is a panel that generates work.
Which results are findings and which are consequences of the weight loss
Three different explanations for the same abnormal number, and how to tell them apart.
STEP 5 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Seasonal use, holiday use, and the honest state of the evidence
The vocabulary is borrowed, the rationale is usually mechanistic, and the outcome data does not exist.
What a low result means when intake has halved
What the trials measured, which in the case of micronutrients is very little.
Grams per kilogram of what? The denominator problem in protein guidance
Where the familiar figures come from, what populations they were measured in, and how far the extrapolation reaches.
Three weeks off is a fresh start, whether or not you want one
Supply interruption is the commonest cause of unplanned re-titration in this market, and it is almost never framed that way.
SELECT extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
STEP 3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
On-off cycling, and the argument from receptor biology that does not hold
The schedules in circulation, described accurately, with their evidentiary status attached.
On-off cycling, and the argument from receptor biology that does not hold
The schedules in circulation, described accurately, with their evidentiary status attached.
Adverse events by dose, adverse events by week
Almost every figure in circulation about tolerability comes from six publications. This is what they say.
What the anaesthetists said, and then said again
The evidence is real, modest, and mostly retrospective. The guidance is correspondingly cautious and has been revised toward individualisation.
Holding the dose before surgery: for whom, for how long
This is the single interaction with ordinary medical care that patients most need to disclose, and it is the one most often not asked about.